Johnson & Johnson Unveils New San Francisco Bay Campus to Accelerate Healthcare Innovation

Source: Instrument Family, unauthorized reproduction is prohibited, and reprinting is allowed 24 hours later.

Eastern Time on September 20, it was reported that Johnson & Johnson opened in Brisbane, California (U.S. Business News).San Francisco Bay Campus, this is a state-of-the-art R&D facility located in the Bay Area,This bay area is one of the most mature global innovation and entrepreneurship centers in the world.。

It is reported that this facility, which covers nearly 200,000 square feet, will accommodate up to 400 employees, more than doubling Johnson & Johnson's R&D operations in the Bay Area.The campus bridges critical technological capabilities by bringing together Janssen Research & Development, Johnson & Johnson Innovation, and Johnson & Johnson Medical Technologies. It willFurther integrate the company into the Bay Area innovation ecosystem to strengthen and increase collaboration with innovators to accelerate growth.

01

Scientists' Home

San Francisco Bay Campus

It is reported that this new research baseLocated near the birthplace of biotechnology, it will become a home for scientists., they focus on utilizing cutting-edge technologies such as gene and RNA therapies as well as advanced data science,Seeking new solutions for all diseases from infectious diseases to retinal diseases.

Thanks to its Bay Area location, the new site will also enable Silicon Valley healthcare entrepreneurs and other researchers to collaborate with company scientists to help advance the next great healthcare breakthrough.

And Joaquin Duato, CEO of Johnson & Johnson, said: "Johnson & Johnson's expansion in the Bay Area demonstrates their commitment to integrating science and technology to deliver transformative healthcare solutions.." In this campus, their talented team will leverage their diverse experiences and expertise to address society's greatest health challenges, creating a better future for patients.

The R&D focus of its new site covers Janssen's therapeutic areas and key functions.Including emerging science and technologies such as gene and RNA therapies, new treatments and approaches for retinal and infectious diseases, and advanced data science, including artificial intelligence and machine learning.The co-location expertise of this site will enable the company's world-class discovery engine and industry-leading pipeline to be expanded.

And they stated, "Their new state-of-the-art scientific facility in the Bay Area will further enhance their R&D capabilities and transform the way they discover, develop, and deliver innovative drugs faster and more efficiently. This is achieved by integrating drug discovery, data science, and digital health."Their goal is to accelerate the growth of our world-class product portfolio and deliver better health outcomes for people around the world."Dr. James Merson, Head of the San Francisco Bay Campus Website and Global Therapeutic Area Head, Infectious Diseases, Janssen Research & Development, LLC."

Since 2014, the Johnson & Johnson Innovation Center in California has been promoting investment and collaboration with academic and industry partners in the Bay Area and greater California ecosystem to accelerate early-stage healthcare innovations.The San Francisco Bay Area campus and the company's JLABS @ South San Francisco will continue to enable the company to build strong relationships with entrepreneurs, scientists, and investors to support and invest in highly differentiated innovations that extend and improve lives everywhere.Moreover, in view of the integration of healthcare and technology in this region, the company will pay more attention to the Johnson & Johnson Technology Organization to enhance its ability to create innovative digital solutions for the promotion of human health.

Based on Johnson & Johnson's long-term commitment to reducing the environmental impact of its operations by utilizing its expertise and resources, the Bay Area Center was designed as a high-performance green campus, reinforcing the company’s commitment to being a responsible steward in creating a healthy and more sustainable future.The goal is to secure a LEED Silver certification for the new site, the most widely used green building rating system in the world.

02

Committed to Health

135 Years of Johnson & Johnson

Johnson & Johnson, founded in 1886, is one of the most comprehensive healthcare enterprises globally, with a wide range of business operations covering three major fields: medical devices, pharmaceuticals, and consumer products.Headquartered in New Brunswick, New Jersey, USA, Johnson & Johnson has more than 260 operating companies across 60 countries and regions globally, with over 130,000 employees worldwide. For this reason, over the past 135 years, the company has remained committed to advancing health care, helping people stay healthy at every age and stage of life.

The fields targeted by its medical devices include:Women's Health Care, Diabetes, Minimally Invasive Surgery, Wound Suturing, Cardiovascular Health, Bone Health, Equipment Sterilization, Diagnostic Products and ServicesJohnson & Johnson believes that health is the foundation of a vibrant life, thriving communities, and continuous progress.

According to the results published in Fortune and Business Week in 1997, Johnson & Johnson ranked 20th globally in terms of market value.And ranked among the top ten most enviable companies in the United States, with a global turnover of up to 275 billion US dollars in 1999.Global revenue reached US$82.6 billion in 2020, with a global R&D investment of US$12.2 billion.

Currently, as a global healthcare enterprise with extensive worldwide operations and a comprehensive multinational presence, Johnson & Johnson is committed to promoting human health and building a better society through its broad influence.While striving to improve the accessibility and affordability of medicines, creating healthier communities, we are committed to enabling people around the world to enjoy physical and mental well-being in a healthy environment, integrating care, science, and wisdom.A Mission to Bring About Profound Changes for the Development of Human Health.

Since 1985, as one of the first multinational enterprises to enter the Chinese market since the reform and opening up, Johnson & Johnson established Xi'an Janssen Pharmaceutical Co., Ltd. in China. Over the years, Johnson & Johnson has been committed to providing high-quality innovative products to meet the growing healthcare needs, bringing health to Chinese patients and consumers, and building a Healthy China.Today, all of Johnson & Johnson's global businesses, including medical devices, pharmaceuticals, consumer health products, and Vision, have entered China and have become leaders in their respective fields. Currently, Johnson & Johnson has more than 10 legal entities and 9 major supply chain bases in China, located in cities such as Beijing, Shanghai, Guangzhou, Suzhou, and Xi'an, with approximately 11,000 employees.。

Its Johnson & Johnson China headquarters is located in Shanghai,With multiple registered companies and production factories in Xuhui District, Pudong New Area, Minhang District, etc. of Shanghai, it is one of the top 100 tax-paying foreign enterprises in Shanghai.China is the fastest-growing region for Johnson & Johnson globally. In 2019, Johnson & Johnson's global executive committee announced in Beijing that China would be positioned as a global innovation engine.

Moreover, Johnson & Johnson is a leading enterprise supporting the Shanghai Municipal Government in building a global innovation hub. As one of Johnson & Johnson's four global open innovation platforms, Shanghai plays a pivotal role.By leveraging the company’s resources, expertise, and regional advantages in the Asia-Pacific and globally, we support the development of local startups and contribute breakthrough healthcare solutions to patients and consumers worldwide.In 2021, Johnson & Johnson China was recognized by the Shanghai Municipal Government as the first foreign-funded open innovation platform.

03

Transformation: Its business overall showed a downward trend.

It was reported that in March this year, Johnson & Johnson announced that its medical device business (Johnson & Johnson Medical Devices) would officially be renamed globally to ""Johnson & Johnson MedTech". This brand-new identity marks that Johnson & Johnson Medical will truly transform intoAn innovative enterprise centered on patients and driven by business growth.

Johnson & Johnson MedTech's business sectors globally encompass surgery, orthopedics, ophthalmology, as well as cardiovascular and specialized solutions, with main brands including: Ethicon, DePuy Synthes, Biosense Webster, Cerenovus, Acclarent, and ACUVUE.According to Johnson & Johnson's announced 2021 global performance, the medical device business revenue reached 27.06 billion U.S. dollars, increasing by 17.9% year-on-year. However, this remarkable performance did not continue into the first half of this year.

On the 16th of this month, Johnson & Johnson stated that the announced repurchase plan has no time limit, and the company can choose to suspend it for a period or even stop it.As of July 22, the company had approximately 2.6 billion outstanding common shares. The company officially announced that it is not expected to incur debt for the purpose of repurchasing shares.Moreover, Johnson & Johnson reiterated its full-year 2022 guidance for adjusted operational sales growth and earnings per share at 6.5% to 7.5% and $10.65 to $10.75, respectively.As of the close on the 28th, JNJ's share price rose more than 0.86% to $166.360 per share.

ItsAccording to the Q2 2022 performance announced by Johnson & Johnson, the company's total sales were $24.02 billion, representing a year-on-year increase of 3%.Net profit was US$4.814 billion, a year-on-year decrease of 23.3%.. By business division, medical technology businessSales revenue of $6.898 billion, a year-on-year decrease of 1.1%.; Consumer Health BusinessSales revenue of $3.805 billion, a year-on-year decrease of 1.3%; Pharmaceutical sales reached $13.317 billion, a year-on-year increase of 6.7%.

Johnson & Johnson's revenue in the first quarter was $23.4 billion, slightly below market expectations, with a profit of approximately $5.15 billion, down about 17%.CFO Wolk stated that this is mainly due to weak demand for COVID-19 vaccines. He added that the company expects currency pressures to result in a total negative impact of $4 billion. These market dynamics have already affected Johnson & Johnson's medical technology business unit, with revenue in the second quarter declining compared to the same period last year.In the U.S., sales of medical technology increased by 1.6%, while outside the U.S., foreign exchange pressures and COVID-19 related restrictions led to a 3.6% decline in sales.

As of July 22, 2022, the companyThe company has approximately 2.6292 billion issued ordinary shares.The company does not expect to incur debt as a result of the stock repurchase program. Johnson & Johnson reaffirmed their adjusted operational sales.Sales increased by 7% to $97.8 billion and adjusted operational earnings per share of $10.70, or the midpoint of guidance for full-year growth of 9.2%.

04

JLABS @ SSF

Birthplace of Biotechnology

It is the first standalone Johnson & Johnson Innovation - JLABS incubator located in the birthplace of biotechnology.The San Francisco Bay Area is home to the first batch of biotechnology companies, renowned academic and medical institutions, cutting-edge technology companies, top venture capitalists, and world-class scientists., is an ideal location for Johnson & Johnson Innovation – JLABS to establish its first standalone site.

JLABS @ South San Francisco (JLABS @ SSF)March 3, 2015: Opened its doors to innovative life science startups.Since then, JLABS @ SSF has established a world-classInnovators Community, attracting top entrepreneurs, researchers, investors, and industry partners, they are all working towards a common goal,That is, to provide innovative solutions to patients and consumers more quickly.

JLABS @ SSF has a non-competitive collaborative atmosphere,This state-of-the-art 30,000-square-foot facility can accommodate 30-40 companies, offering JLABS residents a combination of shared and private specialized laboratory facilities and office spaces.Its value-added services, such as operational support, educational programs, and active resource and investor centers, are just a small part of the potential success offerings for JLABS resident companies.

Their Bay Area startup incubator's focus laboratory equipment is equipped at each JLABS office location.The most advanced laboratory instruments and equipment,And this is what the original JLABS resident startup needed to start and operate on the first day.

This capital-efficient model requires time and investment, eliminating the usual setup that startups typically need.JLABS provides manufacturer training and additional resources for general and specialized equipment, including the following:：

Cell Culture Laboratory (Vitamin 1 and BSL2)

Biological safety cabinet, incubator, vibrating screen, centrifuge, microscope

Chemical Laboratory

Fume hood, High-performance liquid chromatography, Low-temperature thermostat, Freeze dryer

Core Laboratory Facilities

Autoclave, Glass Cleaning, Dry Ice and Wet Ice, Nano Pure Water, Refrigeration, Laboratory Workbench

General Research Laboratory

Fluorescence Quantitative PCR, Thermal Cycler, Plate Reader, Gel Imaging, Flow Cytometry, Microscopy

Special equipment includes

Ultra-high pressure sterilization, Perfluorides, Flow cytometer, Gene sequencing equipment

——

Despite the decline in Johnson & Johnson's previous transformation business, it has not hindered its progress. Instead, it has once again broken through by establishing a solid foundation for its research with advanced R&D facilities. It is believed that, in the future, with innovative development and support across various fields, Johnson & Johnson will achieve more breakthroughs, benefiting patients' health. Medical Device House will continue to monitor its subsequent development.